Table 2. Relationship between RSPO3 expression and the clinicopathological parameters of ovarian cancer.
| Clinicopathological parameters | n | RSPO3 expression | P | |
|---|---|---|---|---|
| Low | High | |||
| Age (y) | 0.415 | |||
| >60 | 30 | 14 | 16 | |
| ≤60 | 103 | 57 | 46 | |
| Menopausal status | 0.857 | |||
| Yes | 84 | 44 | 40 | |
| No | 49 | 27 | 22 | |
| Tumor size (cm) | 0.523 | |||
| >5 | 105 | 58 | 47 | |
| ≤5 | 28 | 13 | 15 | |
| Ascites | 0.422 | |||
| Yes | 100 | 51 | 49 | |
| No | 33 | 20 | 13 | |
| Lymph node metastasis | 0.023 | |||
| Yes | 40 | 15 | 25 | |
| No | 93 | 56 | 37 | |
| Distant metastasis | 0.040 | |||
| Yes | 17 | 5 | 12 | |
| No | 116 | 66 | 50 | |
| FIGO stage | 0.020 | |||
| III–IV | 96 | 45 | 51 | |
| I–II | 37 | 26 | 11 | |
| LVSI | <0.001 | |||
| Yes | 21 | 3 | 18 | |
| No | 112 | 68 | 44 | |
FIGO, International Federation of Gynecology and Obstetrics; LVSI, lymphovascular space invasion.